{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:55:56Z","timestamp":1793796956577,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23-00119"],"award-info":[{"award-number":["PI23-00119"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24-01630"],"award-info":[{"award-number":["PI24-01630"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46312-4","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:47:24Z","timestamp":1775706444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOCS1-based therapeutic peptides improve liver disease and metabolic dysfunction in obesity and diabetes"],"prefix":"10.1038","volume":"16","author":[{"given":"M.","family":"Soto-Catal\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Opazo-R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Espadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romero-Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"G\u00f3mez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Egido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mas-Fontao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"46312_CR1","unstructured":"Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (2023)."},{"key":"46312_CR2","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal, F., Neuschwander-Tetri, B. A., Loomba, R. & Rinella, M. E. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease. Hepatology 79, 1212\u20131219 (2024).","journal-title":"Hepatology"},{"key":"46312_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"6","key":"46312_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal, A. J. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 16(6), 377\u2013386 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46312_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","volume":"17","author":"D Ferguson","year":"2021","unstructured":"Ferguson, D. & Finck, B. N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 484 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"46312_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels, S. et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22, 1\u20139 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"46312_CR7","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson, S. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J. Hepatol. 62, 1148\u20131155 (2015).","journal-title":"J. Hepatol."},{"key":"46312_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"46312_CR9","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. & Targher, G. NAFLD: A multisystem disease. J. Hepatol. 62, S47\u2013S64 (2015).","journal-title":"J. Hepatol."},{"key":"46312_CR10","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1074\/jbc.M116.752519","volume":"292","author":"SY Shi","year":"2017","unstructured":"Shi, S. Y. et al. Janus Kinase 2 (JAK2) dissociates hepatosteatosis from hepatocellular carcinoma in mice. J. Biol. Chem. 292, 3789\u20133799 (2017).","journal-title":"J. Biol. Chem."},{"key":"46312_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","volume":"14","author":"F Marra","year":"2008","unstructured":"Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G. & Tiribelli, C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 14, 72\u201381 (2008).","journal-title":"Trends Mol. Med."},{"key":"46312_CR12","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.aohep.2020.06.010","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao, J., Qi, Y. F. & Yu, Y. R. STAT3: A key regulator in liver fibrosis. Ann. Hepatol. 21, 100224 (2021).","journal-title":"Ann. Hepatol."},{"key":"46312_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010119","author":"J Liu","year":"2023","unstructured":"Liu, J., Wang, F. & Luo, F. The role of JAK\/STAT pathway in fibrotic diseases: Molecular and cellular mechanisms. Biomolecules https:\/\/doi.org\/10.3390\/biom13010119 (2023).","journal-title":"Biomolecules"},{"key":"46312_CR14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","volume":"175","author":"M Grohmann","year":"2018","unstructured":"Grohmann, M. et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 175, 1289-1306.e20 (2018).","journal-title":"Cell"},{"key":"46312_CR15","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/febs.13709","volume":"283","author":"EN Gurzov","year":"2016","unstructured":"Gurzov, E. N., Stanley, W. J., Pappas, E. G., Thomas, H. E. & Gough, D. J. The JAK\/STAT pathway in obesity and diabetes. FEBS J. 283, 3002\u20133015 (2016).","journal-title":"FEBS J."},{"key":"46312_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1042\/BJ20140143","volume":"461","author":"S Galic","year":"2014","unstructured":"Galic, S., Sachithanandan, N., Kay, T. W. & Steinberg, G. R. Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity. Biochem. J. 461, 177\u2013188 (2014).","journal-title":"Biochem. J."},{"issue":"6","key":"46312_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7(6), 454\u2013465 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"46312_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20031675","volume":"199","author":"T Yoshida","year":"2004","unstructured":"Yoshida, T. et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J. Exp. Med. 199, 1701\u20131707 (2004).","journal-title":"J. Exp. Med."},{"key":"46312_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20070820","volume":"205","author":"KJ Riehle","year":"2008","unstructured":"Riehle, K. J. et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J. Exp. Med. 205, 91 (2008).","journal-title":"J. Exp. Med."},{"key":"46312_CR20","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3390\/cancers14102549","volume":"14","author":"R Masuzaki","year":"2022","unstructured":"Masuzaki, R. et al. Suppressors of cytokine signaling and hepatocellular carcinoma. Cancers 14, 2549 (2022).","journal-title":"Cancers"},{"key":"46312_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1681\/ASN.2016020237","volume":"28","author":"C Recio","year":"2017","unstructured":"Recio, C. et al. Suppressor of cytokine signaling-1 peptidomimetic limits progression of diabetic nephropathy. J. Am. Soc. Nephrol. 28, 575\u2013585 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"46312_CR22","doi-asserted-by":"publisher","first-page":"e001242","DOI":"10.1136\/bmjdrc-2020-001242","volume":"8","author":"L Opazo-R\u00edos","year":"2020","unstructured":"Opazo-R\u00edos, L. et al. Anti-inflammatory, antioxidant and renoprotective effects of SOCS1 mimetic peptide in the BTBR ob\/ob mouse model of type 2 diabetes. BMJ Open Diabetes Res. Care 8, e001242 (2020).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"46312_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103670","volume":"84","author":"S Bernal","year":"2025","unstructured":"Bernal, S. et al. Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease. Redox Biol. 84, 103670 (2025).","journal-title":"Redox Biol."},{"key":"46312_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073965","volume":"23","author":"L Opazo-R\u00edos","year":"2022","unstructured":"Opazo-R\u00edos, L. et al. Meta-inflammation and de novo lipogenesis markers are involved in metabolic associated fatty liver disease progression in BTBR ob\/ob mice. Int. J. Mol. Sci. 23, 3965 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"46312_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-0704-6_11","volume":"2164","author":"ME Minniti","year":"2020","unstructured":"Minniti, M. E., Ahmed, O. & Pedrelli, M. Enzymatic quantification of liver lipids after Folch extraction. Methods Mol. Biol. 2164, 101\u2013108 (2020).","journal-title":"Methods Mol. Biol."},{"key":"46312_CR26","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db09-0848","volume":"59","author":"S Mas","year":"2010","unstructured":"Mas, S. et al. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. Diabetes 59, 1292 (2010).","journal-title":"Diabetes"},{"key":"46312_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1210\/en.2006-0644","volume":"148","author":"A Gonzalez-Rodriguez","year":"2007","unstructured":"Gonzalez-Rodriguez, A. et al. Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes. Endocrinology 148, 594\u2013608 (2007).","journal-title":"Endocrinology"},{"key":"46312_CR28","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1074\/jbc.M115.649483","volume":"290","author":"V Pardo","year":"2015","unstructured":"Pardo, V., Gonz\u00e1lez-Rodr\u00edguez, \u00c1., Guijas, C., Balsinde, J. & Valverde, \u00c1. M. Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. J. Biol. Chem. 290, 11663\u201311677 (2015).","journal-title":"J. Biol. Chem."},{"key":"46312_CR29","first-page":"815","volume":"12","author":"X Feng","year":"2024","unstructured":"Feng, X., Zhang, R., Yang, Z., Zhang, K. & Xing, J. Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism. J. Clin. Transl. Hepatol. 12, 815 (2024).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"46312_CR30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i1.75","volume":"29","author":"GY Wang","year":"2023","unstructured":"Wang, G. Y., Zhang, X. Y., Wang, C. J. & Guan, Y. F. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies. World J. Gastroenterol. 29, 75 (2023).","journal-title":"World J. Gastroenterol."},{"key":"46312_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9, 798\u2013809 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"46312_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.7150\/ijbs.7.536","volume":"7","author":"H Wang","year":"2011","unstructured":"Wang, H., Lafdil, F., Kong, X. & Gao, B. Signal transducer and activator of transcription 3 in liver diseases: A novel therapeutic target. Int. J. Biol. Sci. 7, 536\u2013550 (2011).","journal-title":"Int. J. Biol. Sci."},{"key":"46312_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaut.2013.07.008","volume":"46","author":"YR Deng","year":"2013","unstructured":"Deng, Y. R. et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J. Autoimmun. 46, 25\u201334 (2013).","journal-title":"J. Autoimmun."},{"key":"46312_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.09.001","author":"R Kandhi","year":"2024","unstructured":"Kandhi, R., Menendez, A., Ramanathan, S. & Ilangumaran, S. Regulation of high-fat diet-induced liver fibrosis by SOCS1 expression in hepatic stellate cells. J. Clin. Exp. Hepatol. https:\/\/doi.org\/10.1016\/j.jceh.2023.09.001 (2024).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"46312_CR35","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1161\/ATVBAHA.114.304144","volume":"34","author":"C Recio","year":"2014","unstructured":"Recio, C. et al. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase\/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice. Arterioscler. Thromb. Vasc. Biol. 34, 1953\u20131960 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"46312_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-014-0458-1","volume":"110","author":"C Recio","year":"2015","unstructured":"Recio, C. et al. Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice. Basic Res. Cardiol. 110, 1\u201311 (2015).","journal-title":"Basic Res. Cardiol."},{"issue":"7","key":"46312_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: Current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol 16(7), 411\u2013428 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"key":"46312_CR38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/dom.14272","volume":"23","author":"C Beysen","year":"2021","unstructured":"Beysen, C. et al. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. Diabetes. Obes. Metab. 23, 700\u2013710 (2021).","journal-title":"Obes. Metab."},{"issue":"15","key":"46312_CR39","doi-asserted-by":"publisher","first-page":"14169","DOI":"10.1007\/s00432-023-05106-1","volume":"149","author":"T Yang","year":"2023","unstructured":"Yang, T., Qiao, S. & Zhu, X. High-dose radiation-resistant lung cancer cells stored many functional lipid drops through JAK2\/p-STAT3\/FASN pathway. J. Cancer Res. Clin. Oncol. 149(15), 14169\u201314183 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"46312_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107351","volume":"300","author":"Y Fan","year":"2024","unstructured":"Fan, Y. et al. STAT3 activation of SCAP-SREBP-1 signaling upregulates fatty acid synthesis to promote tumor growth. J. Biol. Chem. 300, 107351 (2024).","journal-title":"J. Biol. Chem."},{"key":"46312_CR41","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cyto.a.24783","volume":"103","author":"H Nakashima","year":"2023","unstructured":"Nakashima, H. et al. Novel phenotypical and functional sub-classification of liver macrophages highlights changes in population dynamics in experimental mouse models. Cytom. Part A 103, 902\u2013914 (2023).","journal-title":"Cytom. Part A"},{"key":"46312_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00357","volume":"5","author":"HM Wilson","year":"2014","unstructured":"Wilson, H. M. SOCS proteins in macrophage polarization and function. Front. Immunol. 5, 104201 (2014).","journal-title":"Front. Immunol."},{"issue":"6","key":"46312_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15(6), 349\u2013364 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46312_CR44","doi-asserted-by":"publisher","first-page":"8162421","DOI":"10.1155\/2017\/8162421","volume":"2017","author":"A Alisi","year":"2017","unstructured":"Alisi, A. et al. The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications. Mediat. Inflamm. 2017, 8162421 (2017).","journal-title":"Mediat. Inflamm."},{"key":"46312_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115528","volume":"24","author":"LA Videla","year":"2023","unstructured":"Videla, L. A., Valenzuela, R., Del Campo, A. & Z\u00fa\u00f1iga-Hern\u00e1ndez, J. Omega-3 lipid mediators: Modulation of the M1\/M2 macrophage phenotype and its protective role in chronic liver diseases. Int. J. Mol. Sci. 24, 15528 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"46312_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113547","volume":"221","author":"S La Manna","year":"2021","unstructured":"La Manna, S. et al. Cyclic mimetics of kinase-inhibitory region of suppressors of cytokine signaling 1: Progress toward novel anti-inflammatory therapeutics. Eur. J. Med. Chem. 221, 113547 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"46312_CR47","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bph.15330","volume":"178","author":"S Bernal","year":"2021","unstructured":"Bernal, S. et al. Protective effect of suppressor of cytokine signalling 1-based therapy in experimental abdominal aortic aneurysm. Br. J. Pharmacol. 178, 564\u2013581 (2021).","journal-title":"Br. J. Pharmacol."},{"key":"46312_CR48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/antiox9080754","volume":"9","author":"S La Manna","year":"2020","unstructured":"La Manna, S. et al. Antioxidant effects of PS5, a peptidomimetic of suppressor of cytokine signaling 1, in experimental atherosclerosis. Antioxidants 9, 754 (2020).","journal-title":"Antioxidants"},{"issue":"8","key":"46312_CR49","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s11739-023-03426-1","volume":"18","author":"S Corrao","year":"2023","unstructured":"Corrao, S. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: A reasoned literature analysis. Intern. Emerg. Med. 18(8), 2157\u20132161 (2023).","journal-title":"Intern. Emerg. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46312-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46312-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46312-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:02:20Z","timestamp":1780016540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46312-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46312"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46312-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MSC, LPR, SMF, JE and CGG are inventors on a patent application for SOCS peptidomimetics. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16682"}}